The COMPASSION-16 trial by Xiaohua Wu and colleagues addresses a crucial need in the management of advanced cervical cancer by evaluating cadonilimab, a novel bispecific antibody targeting PD-1 and ...

FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures ...

In the current climate of capital constraints, tariffs, and policy uncertainty, as well as changing regulatory dynamics, ...

The key news from the release was that while the company outperformed revenue estimates—reporting $28.2 million (GAAP) compared to the expected $27.03 million—profitability came under pressure, with a ...

A study published in the International Journal of Radiation Oncology*Biology*Physics demonstrates that clinicopathology (CP) ...

Sava Technologies announced today that it raised $19 million in a Series A financing round to support its wearable biosensor ...

Q2 2025 Management View Kabir Kumar Nath, CEO, announced the appointment of Justin Gover, former CEO of GW Pharmaceuticals, ...

With Human Research Ethics Committee (HREC) approval already secured, Oragenics is working closely with Southern Star to complete site selection, finalize investigator agreements, and prepare for ...

Q2 2025 Earnings Call Transcript July 30, 2025 Anika Therapeutics, Inc. reports earnings inline with expectations. Reported ...

Kedrion Biopharma receives US FDA orphan drug designation for Coagadex to treat acquired Factor X deficiency: Fort Lee, New Jersey Thursday, July 31, 2025, 15:00 Hrs [IST] Kedrion ...

We spoke with endocrinologists to explore the potential of artificial intelligence in the management of chronic disease, including diabetes, obesity, and PCOS.

In early-phase drug development, the success of a dose escalation study depends not only on the design but also on the speed and accuracy of decision-making across cohorts. Delays in progressing ...